GRANTS
WE ARE GRATEFUL FOR THE FUNDING AND SUPPORT FROM THE FOLLOWING ORGANIZATIONS
National Institutes of Health (NIH)
National Institute for Allergy and Infectious Diseases (NIAID)
National Institute for Aging Research (NIA)
New York State Biodefense Commercialization Fund
University of Pittsburgh
The Bill and Melinda Gates Foundation
IAVI International AIDS Vaccine Initiative iavi.org
NIA | National Institute on Aging
An RSV Prefusion F Vaccine that Overcomes Immunosenescence
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA
NIAID | National Institute of Allergy & Infectious Diseases
Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine
An Adjuvant for an RSV Prefusion F Vaccine that Safely Protects Infants Via Maternal Vaccination
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA
Conformational Stabilization of the HIV-1 Env Trimer
NEW YORK STATE BIODEFENSE COMMERCIALIZATION FUND
Developing Potent Subunit Vaccines for Infectious Diseases
$750,000 - September 6, 2022 - NY.gov
Through its unique protein engineering technology, Calder Biosciences is developing more
potent vaccine immunogens that provide better immunity and protection
NATIONAL INSTITUTES OF HEALTH (NIH) | U.S. DEPT OF HEALTH & HUMAN SERVICES
NATIONAL INSTITUTE ON AGING (NIA)
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA
$2,861,512 - CFDA Award R44AG059371
An RSV Prefusion F Vaccine that Overcomes Immunosenescence
$1,928,617 - 2020 - CFDA Award R44AG064107
An RSV Prefusion F Vaccine that Overcomes Immunosenescence -
$299,740 - 2019 - CFDA Award R44AG064107
NATIONAL INSTITUTE OF ALLEGIES AND INFECTIOUS DISEASES (NIAID)
An Adjuvant for an RSV Prefusion F Vaccine that Safely Protects Infants Via Maternal Vaccination $599,742 - 2018 - CFDA Award R43AI140941
Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine
$1,499,167 - CFDA Award R44AI112124
Conformational Stabilization of the HIV-1 Env Trimer
$2,992,950 - CFDA Award R44AI091507
A Universal Flu Vaccine Based on Conformationally Locked Soluble Headless HA
$224,905 - CFDA Award R43AI118087
Read more about Calder's Team.
Read more about Calder's Programs.